Lori Anne Kunkel, Director at Enliven Therapeutics, Inc. (ELVN), sold 10,000 shares at $34.28 ($345K) on 2026-06-05, disclosed to the SEC on 2026-06-09.
Scheduled sale ($345k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.28 | 7,779 | $267K | 77.2% |
| 2 | $35.36 | 1,867 | $66K | 19.1% |
| 3 | $35.82 | 354 | $13K | 3.7% |
| Total | $34.54 avg | 10,000 | $345K | 100% |
| Filing → |
| LOXO | SELL | 2018-10-03 | $852K | — | Filing → |
| LOXO | SELL | 2018-06-18 | $14.1M | — | Filing → |
| LOXO | SELL | 2018-04-24 | $782K | — | Filing → |